Merck KGaA, Darmstadt, Germany, Announces New Appointments in Global R&D and Strategy Leadership for Healthcare Business Sector

Merck KGaA, Darmstadt, Germany today announced new appointments in Global R&D and Strategy leadership for the Healthcare business sector.

13 Jan 2022 | Darmstadt, Germany

Darmstadt, Germany, January 13, 2022– Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced new appointments in Global R&D and Strategy leadership for the Healthcare business sector. Danny Bar-Zohar, MD, will become Global Head of R&D and Joern-Peter Halle, PhD, will become Chief Strategy Officer.

“At the critical intersection of R&D and Strategy is a very unique opportunity to make bold choices that best position us to deliver on our fullest innovative potential for patients and for our company,” said Peter Guenter, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Healthcare. “With Danny and Joern-Peter, we have the perfect combination of collaboration, strategic vision and leadership, in addition to world-class experience and expertise, to move beyond the status quo and lead our innovation engine for today and for the future.”

As Global Head of R&D, Bar-Zohar will lead Research and Development, including Medical Affairs. Bar-Zohar joined Merck KGaA, Darmstadt, Germany, in November 2020 as Executive Vice President, Global Head of Development. He has more than a decade of leadership experience in pharma, having worked previously at Novartis and Teva. He brings global drug development experience from strategy to execution to this position, across almost every modality in drug development, including small molecules, therapeutic proteins, antibodies and gene therapy. Bar-Zohar’s proven track record will serve to further advance the highly innovative and differentiated early-stage assets the research teams at Merck KGaA, Darmstadt, Germany, have delivered into development in recent years.

As Chief Strategy Officer, Halle will lead Strategy and Business Development. Halle brings significant experience to this role, having previously served as Executive Vice President, Global Head of Research for the last 18 months, leading discovery through pre-clinical efforts for the company’s Oncology/Immuno-Oncology and Immunology therapeutic areas. Halle also served as Senior Vice President, Head of Immuno-Oncology research, and Senior Vice President, Head of External Innovation. Halle brings more than 25 years of industry experience to this position. He joined Merck KGaA, Darmstadt, Germany, in 2005.

Both Bar-Zohar and Halle will continue to be part of the Healthcare Executive Committee and be based at the company’s global headquarters in Darmstadt, Germany.


For more information, please contact Gangolf Schrimpf

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany, generated sales of € 17.5 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Related News

  1. Press Releases

    Merck KGaA, Darmstadt, Germany, Provides Update on Xevinapant Program in Locally ...

    Merck KGaA, Darmstadt, Germany, today announced the discontinuation of the Phase III randomized TrilynX study.